Image Not Found On Media Library
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
      • Comprehensive Market Access Launch Strategy
      • Market Access Landscape Analysis
      • HTA Planning and Reimbursement Evidence Strategy
      • Negotiation & Stakeholder Engagement Strategy
      • Portfolio & Life Cycle Strategy
      • Expert-Led Training & Customized Workshops
  • REPORTS
    • NEW – Pre-Order CRaFT 2025
    • 2024 CRaFT Report
    • DRD Market Access Trends & Insights
    • Oncology Market Access Trends & Insights
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-r
Image Not Found On Media Library
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
      • Comprehensive Market Access Launch Strategy
      • Market Access Landscape Analysis
      • HTA Planning and Reimbursement Evidence Strategy
      • Negotiation & Stakeholder Engagement Strategy
      • Portfolio & Life Cycle Strategy
      • Expert-Led Training & Customized Workshops
  • REPORTS
    • NEW – Pre-Order CRaFT 2025
    • 2024 CRaFT Report
    • DRD Market Access Trends & Insights
    • Oncology Market Access Trends & Insights
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

Number of active negotiations (34) at lowest point since March 2017

December 6, 2019
-
Market Access News
-
Posted by MORSE - 3 min read.

pan-Canadian Pharmaceutical Alliance (pCPA): November 2019 Trends and Insights

 

The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the November 30, 2019 status of brand negotiations.  Highlights since the last update include:

  • 6 products completed CADTH review, for a total of 9 files under consideration;
  • 4 products initiated pCPA negotiations, for a total of 34 active negotiations;
  • 12 negotiations completed for a total of 294 completed negotiations;
  • No negotiations closed, for a total of 47 closed negotiations; and
  • 2 files closed without negotiations, for a total of 72 declined negotiations.

  

Files Under pCPA Consideration

 

6 new drug products received a CDEC recommendation or pERC notification to implement in November 2019, for a total of approximately 9 products under pCPA Consideration.

 

Brand Name Generic Name Manufacturer Indication Recommendation
Cimzia certolizumab pegol UCB Canada Psoriasis, moderate to severe plaque Conditional
Revestive teduglutide Shire Short Bowel Syndrome (SBS), pediatrics Conditional
Takhzyro lanadelumab Shire Hereditary angioedema, prevention Conditional
Verkazia cyclosporine Santen Severe vernal keratoconjunctivitis, pediatric (≥4 years) Conditional
Idhifa Enasidenib Celgene Acute Myeloid Leukemia (AML)
Does not recommend
Vitrakvi Larotrectinib Bayer Neurotrophic Tyrosine Receptor Kinase (NTRK) Locally Advanced or Metastatic Solid Tumours
Does not recommend

 

 

Negotiation Initiation

 

The pCPA initiated 4 new negotiations since the last update, for a total of 34 active negotiations.

 

Brand Name Generic Name Manufacturer Indication CADTH Date Time to Initiate
Darzalex Daratumumab Janssen Multiple Myeloma (newly diagnosed) 16 Sep 19 60
Onpattro Patisiran Alnylam Netherlands BV Polyneuropathy in hereditary transthyretin-mediated amyloidosis (hATTR) 25 Jul 19 113
Tegsedi Inotersen Akcea Stage 1 or 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR)  11 Sep 19 (INESSS) CDEC Rec’n Pending 65

(INESSS)

Triamcinolone Hexacetonide Triamcinolone Hexacetonide Medexus subacute and chronic inflammatory joint diseases N/A N/A

*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.

 

 

 

Signals Decoded:

The pCPA has initiated negotiations for two products indicated to treat polyneuropathy in hereditary transthyretin-mediated amyloidosis (hATTR) – Onpattro, which had been the file under current pCPA Consideration for the longest duration, and Tegsedi, based on a List with conditions recommendation from INESSS. Of the new files under pCPA consideration, two (Cimzia, Revestive) have been previously negotiated for other indications.

 

 

Completed

 

Brand Name Generic Name Manufacturer Indication Initiated Duration*
Dovato Dolutegravir

lamivudine

ViiV Healthcare HIV infection Oct 2019 31 days
Lenvima Lenvatinib Eisai unresectable hepatocellular carcinoma, 1st line Sep 2019 61 days
Vyzulta latanoprostene bunod Bausch & Lomb open-angle glaucoma or ocular hypertension Aug 2019 92 days
Cabometyx Cabozantinib Ipsen Renal cell carcinoma Jun 2019 153 days
Skyrizi risankizumab AbbVie Plaque psoriasis Jun 2019 153 days
Cresemba isavuconazole  AVIR Pharma Treatment of invasive aspergillosis and mucormycosis Jul 2019 123 days
Herzuma trastuzumab Teva early and metastatic breast cancer, gastric cancer May 2019 184 days
Soliqua Lixisenatide

insulin glargine

Sanofi-Aventis Diabetes mellitus, Type 2 Apr 2019 214 days
Tagrisso Osimertinib AstraZeneca locally advanced or metastatic NSCLC, 1st line Mar 2019 245 days
Xarelto rivaroxaban Bayer prevention of cardiovascular events in CAD/PAD Mar 2019 245 days
Mavenclad Cladribine EMD Serono relapsing-remitting multiple sclerosis Feb 2019 273 days
Adlyxine lixisenatide Sanofi-Aventis Diabetes mellitus, Type 2 Apr 2018 579 days

*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.

 

 

Signals Decoded:

November saw the pCPA complete 12 negotiations, including 3 that were completed within 3 months, reducing the number of active negotiations by ~20% (42 to 34) in a single month. After completing the first successful negotiation for a GLP-1 receptor agonist (Ozempic) in July of this year, the pCPA has signed a Letter of Intent for a second product (Adlyxine, lixisenatide) from this drug class, ending negotiations that had been ongoing for over a year-and-a-half. At the same time, a deal was also reached for Soliqua which combines lixisenatide with insulin glargine. The pCPA also completed negotiations for the third trastuzumab biosimilar (Herzuma), after signing deals for the first two (Ogivri, Trazimera) last month.

 

 

Not Negotiated

 

Brand Name Generic Name Manufacturer Indication CADTH Date Time to Decision*
Illuvien fluocinolone acetonide intravitreal implant Knight Therapeutics Diabetic Macular Edema 26 Sep 19 50 days
Keytruda Pembrolizumab Merck Metastatic Urothelial Carcinoma, 1st line 21 Oct 19 25 days

*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.

 

 

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

Share
Tags
Biosimilars
CADTH
CDEC
Oncology
Pan Canadian Pharmaceutical Alliance
pCPA
pCPAO
pERC
← PREVIOUS POST
Season’s Greetings from MORSE Consulting
NEXT POST →
Summary of the CADTH Drug Portfolio Information Session November 2019

Contact Us

MORSE Consulting Inc.

Toronto | Ottawa, Canada

+1-647-717-3179 (Toronto)

+1-613-864-8645 (Ottawa)

info@morseconsulting.ca

Pre-Order 2025 Report

2025 Canadian Reimbursement and Forecasting Timelines Report

Social
Connect & Follow:
Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
Number of active negotiations (34) at lowest point since March 2017
Learn More
Learn More